Fundraising FoxHealthtech Startups
18,759 companies tagged Healthtech, with their investors and founders.
Nielsen BioSciences develops biopharmaceutical products that assess or treat immune responses, including skin test antigens for Valley Fever and candida infections, and investigational therapeutics for HPV-related lesions.
0 investors
0 investors
0 investors
Nimbus Healthcare is a telehealth wellness platform offering personalized treatment programs including GLP-1 medical weight loss, hormone optimization, and hair restoration, with medications compounded in its Austin pharmacy and delivered to patients. It provides clinician-led care, async doctor visits, and GLP-1-complementary meal plans to consumers across a range of U.S. states.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
NJ Bio, Inc. is a contract research and contract development and manufacturing organization (CRO/CDMO) providing integrated chemistry and biology services—including antibody-drug conjugates, bioconjugation, protein and antibody production, cell-based assays, nucleotide/oligonucleotide and mRNA synthesis, and bioanalytical work—to biotech and pharmaceutical companies. It is headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania and Mumbai, India.
0 investors
NK-One Therapeutics is a biotechnology company developing a first-in-class intrathecal molecular therapy (SP-SAP) that selectively disables NK-1 receptor pain-signaling neurons in the spine to treat refractory pain in end-stage cancer patients. The therapy is in a Phase 1 clinical trial and is also intended for veterinary use.
0 investors
NKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
NOK Therapeutics is a biotech company developing autologous Natural Killer (NK) cell therapies for cancer treatment that avoid the need for lymphodepletion. The company is an early-stage oncology/immunotherapy business raising capital through a Regulation A+ pre-IPO offering.
0 investors
0 investors
0 investors
0 investors
0 investors